Preview

Колопроктология

Расширенный поиск

ДИАГНОСТИКА, ЛЕЧЕНИЕ И ПРОГНОЗ У ПАЦИЕНТОВ С КАНЦЕРОМАТОЗОМ БРЮШИНЫ ПРИ КОЛОРЕКТАЛЬНОМ РАКЕ (обзор литературы)

https://doi.org/10.33878/2073-7556-2020-19-4-131-149

Полный текст:

Аннотация

Изолированное поражение метастазами брюшины при раке толстой кишки встречается у 1,8% пациентов. Данный тип опухолей характеризуется определенными фенотипическими и молекулярно-генетическими особенностями, что определяет особенности течения заболевания и, соответственно, выбор лечения методов  больных. В настоящем обзоре литературы наряду с описанием основных положений патогенеза заболевания рассмотрены чувствительность и специфичность различных методов диагностики поражения брюшины при раке толстой кишки, выбора системной терапии, необходимости выполнения  хирургического удаления метастазов и проведения внутриперитонеальной гипертермической химиоперфузии.

Об авторах

М. Ю. Федянин
Онкологическое отделение лекарственного лечения (химиотерапевтического) №2 ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия

д.м.н., с.н.с., Доцент кафедры онкологи и гематологии ФНМО РУДН   

SPINкод: 4381-5628

ул. Миклухо-Маклая, д.21, корп.3, Москва, 117198, Россия

тел. +74993441900



А. А. Трякин
Онкологическое отделение лекарственного лечения (химиотерапевтического) №2 ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
д.м.н., г.н.с., Заведующий дневным стационаром МКНЦ им.А.С.Логинова ДЗ г. Москвы. К+31 Сити., Доцент НИИ онкологии БГМУ

ул. Миклухо-Маклая, д.21, корп.3, Москва, 117198, Россия



М. Д. Тер-Ованесов
Онкологическое отделение лекарственного лечения (химиотерапевтического) №2 ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
д.м.н., профессор, заведующий кафедрой онкологи и гематологии ФНМО РУДН

ул. Миклухо-Маклая, д.21, корп.3, Москва, 117198, Россия



С. А. Тюляндин
Онкологическое отделение лекарственного лечения (химиотерапевтического) №2 ФГБУ «НМИЦ онкологии им. Н.Н. Блохина» Минздрава России
Россия
д.м.н., проф. заведующий отделением

ул. Миклухо-Маклая, д.21, корп.3, Москва, 117198, Россия



Список литературы

1. Riihimäki M, Thomsen H, Sundquist K, et al. Clinical landscape of cancer metastases. Cancer Med. 2018 Nov;7(11):5534-5542. doi: 10.1002/cam4.1697.

2. Chu DZ, Lang NP, Thompson C, et al. Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989; 63(2): 364–367. DOI:10.1002/1097-0142(19890115)63:2<364::aid-cncr2820630228>3.0.co;2-v.

3. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88(2): 358–363. DOI: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o.

4. Jayne DG, Fook S, Loi C and Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. The British Journal of Surgery. 2002; 89(12): 1545–1550. DOI:10.1046/j.1365-2168.2002.02274.x.

5. Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016 Dec;17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9.

6. Hugen N, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. Ann Oncol. 2014 Mar;25(3):651-7. doi: 10.1093/annonc/mdt591.

7. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011 Oct 15;117(20):4623-32.

8. Morris V, Overman MJ, Jiang ZQ, et al. Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep;13(3):164-71. doi: 10.1016/j.clcc.2014.06.001.

9. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov; 21(11): 1350-6. doi: 10.1038/nm.3967.

10. Ubink I, van Eden WJ, Snaebjornsson P et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. BJS. 2018; 105: e204–e211. doi: 10.1002/bjs.10788.

11. Yao Q, Qu X, Yang Q, Wei M, Kong B. CLIC4 mediates TGF-beta1-induced fibroblast-to-myofibroblast transdifferentiation in ovarian cancer. Oncol Rep. 2009;22:541–548. DOI:10.3892/or_00000469.

12. Neumann J, Löhrs L, Albertsmeier M, et al. Cancer Stem Cell Markers Are Associated With Distant Hematogenous Liver Metastases But Not With Peritoneal Carcinomatosis in Colorectal Cancer. Cancer Invest. 2015;33(8):354-60. https://doi.org/10.3109/07357907.2015.1047507.

13. Shelygin Yu.A., Pospekhova N.I., Shubin V.P., et al. Epithelial-Mesenchymal Transition and Somatic Alteration in Colorectal Cancer with and without Peritoneal Carcinomatosis. Biomed Res Int. 2014:629496. doi:10.1155/2014/629496.

14. Heublein S, Albertsmeier M, Pfeifer D, et al. Association of differential miRNA expression with hepatic vs. peritoneal metastatic spread in colorectal cancer. BMC Cancer. 2018 ;18(1): 1–10, doi: 10.1186/s12885-018-4043-0.

15. Lemoine L, Sugarbaker P and Van Der Speeten K. Pathophysiology of colorectal peritoneal carcinomatosis: role of the peritoneum. World Journal of Gastroenterology. 2016; 22(34): 7692–7707. doi: 10.3748/wjg.v22.i34.7692.

16. Zebrowski BK, Liu W, Ramirez K, et al. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol. 1999 Jun;6(4):373-8. https://doi.org/10.1007/s10434-999-0373-0.

17. Chia CS, Glehen O, Bakrin N, et al. Intraperitoneal vascular endothelial growth factor: a prognostic factor and the potential for intraperitoneal bevacizumab use in peritoneal surface malignancies. Annals of Surgical Oncology. 2015;22, Supplement 3, pp. 880–887. doi: 10.1245/s10434-015-4644-7.

18. Mikuła-Pietrasik J, Uruski P, Tykarski A, and Ksia˛zek K. The peritoneal “soil” for a cancerous “seed”: a comprehensive review of the pathogenesis of intraperitoneal cancer metastases. Cellular and Molecular Life Sciences. 2018; 75(3): 509–525. doi: 10.1007/s00018-017-2663-1.

19. Marcuello M, Mayol X, Felipe-Fumero E, et al. Modulation of the colon cancer cell phenotype by pro-inflammatory macrophages: a preclinical model of surgery associated inflammation and tumor recurrence. PLoS One. 2018; 13(2), Article ID e0192958. doi: 10.1371/journal.pone.0192958

20. Kojima M, Higuchi Y, Yokota M, et al. Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis. PLoS One. 2014; 9(2), Article ID e88018. DOI: 10.1371/journal.pone.0088018.

21. Kitayama J, Emoto S, Yamaguchi H, et al. CD90(+) mesothelial-like cells in peritoneal fluid promote peritoneal metastasis by forming a tumor permissive microenvironment. PLoSOne. 2014; 9(1), ArticleIDe86516. doi: 10.1371/journal.pone.0086516.

22. Zhang Y, Nowicka A, Solley TN, et al. Stromal cells derived from visceral and obese adipose tissue promote growth of ovarian cancers. PLoS One. 2015; 10(8), Article ID e0136361. doi: 10.1371/journal.pone.0136361

23. Sluiter N, de Cuba E, Kwakman R, et al. Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clinical and Experimental Metastasis. 2016; 33(5): 401–416. doi: 10.1007/s10585-016-9791-0

24. Pretzsch E, Bösch F, Neumann J, et al. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J Oncol. 2019 Sep 19;2019:7407190. doi: 10.1155/2019/7407190.

25. De Cuba EMV, Kwakman R, Van Egmond M et al. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer. Virchows Archiv. 2012; 461(3): 231–243. doi: 10.1007/s00428-012-1287-y.

26. Lambert AW, Pattabiraman DR and Weinberg RA. Emerging biological principles of metastasis. Cell. 2017; vol. 168, no. 4, pp. 670–691. doi: 10.1016/j.cell.2016.11.037

27. Sakamoto M, Takamura M, Ino Y, et al. Involvement of c-src in carcinoma cell motility and metastasis. Japanese Journal of Cancer Research. 2001; 92(9): 941–946. doi: 10.1111/j.1349-7006.2001.tb01184.x

28. Meyers MA. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med. 1973; 119: 198-206. DOI:10.2214/ajr.119.1.198

29. Sugarbaker PH. Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res. 1996; 82: 79-100. doi: 10.1007/978-1-4613-1247-5_6.

30. Heath RM, Jayne DG, O’Leary R, et al. Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer. 2004; 90: 1437-1442. doi: 10.1038/sj.bjc.6601635.

31. Warn R, Harvey P, Warn A, et al. HGF/SF induces mesothelial cell migration and proliferation by autocrine and paracrine pathways. Exp Cell Res. 2001; 267: 258-266. DOI: 10.1006/excr.2001.5240

32. Koumpa FS, Xylas D, Konopka M, et al. Colorectal peritoneal metastases: a systematic review of current and emerging trends in clinical and translational research. Gastroenterol Res Pract. 2019 Apr 1;2019:5180895. https://doi.org/10.1155/2019/5180895

33. Koh JL, Yan TD, Glenn D and Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Annals of Surgical Oncology. 2009; 16(2): 327–333. https://doi.org/10.1245/s10434-008-0234-2

34. Marin D, Catalano C, Baski M, et al. 64-Section multidetector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdominal Imaging. 2010; 35(6): 694–700. doi: 10.1007/s00261-008-9464-9

35. Duhr CD, Kenn W, Kickuth R, et al. Optimizing of preoperative computed tomography for diagnosis in patients with peritoneal carcinomatosis. World Journal of Surgical Oncology. 2011; 9(1): 171. doi: 10.1186/1477-7819-9-171.

36. Esquivel J, Chua TC, Stojadinovic A, et al. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. Journal of Surgical Oncology. 2010; 102(6): 565–570. doi: 10.1002/jso.21601

37. Flicek K, Ashfaq A, Johnson CD, et al. Correlation of radiologic with surgical peritoneal cancer index scores in patients with Pseudomyxoma Peritonei and peritoneal carcinomatosis: how well can we predict resectability? Journal of Gastrointestinal Surgery. 2016; 20(2): 307–312. doi: 10.1007/s11605-015-2880-6.

38. Franiel T, Diederichs G, Engelken F, et al. Multi-detector CT in peritoneal carcinomatosis: diagnostic role of thin slices and multiplanar reconstructions. Abdominal Imaging. 2009; 34(1): 49–54. doi: 10.1007/s00261-008-9372-z.

39. Laghi A, Bellini D, Rengo M, et al. Diagnostic performance of computed tomography and magnetic resonance imaging for detecting peritoneal metastases: systematic review and meta-analysis. La Radiologia Medica. 2017; 122(1): 1–15. doi: 10.1007/s11547-016-0682-x.

40. Liberale G, Lecocq C, Garcia C, et al. Accuracy of FDGPET/CT in colorectal peritoneal carcinomatosis: potential tool for evaluation of chemotherapeutic response. Anticancer Research. 2017;37(2): 929–934. DOI:10.21873/anticanres.11401

41. Pasqual EM, Bertozzi S, Bacchetti S, et al. Preoperative assessment of peritoneal carcinomatosis in patients undergoing hyperthermic intraperitoneal chemotherapy following cytoreductive surgery. Anticancer Research. 2014; 34(5): 2363–2368.

42. Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdominal Imaging. 2008; 33(1): 87–93. doi: 10.1007/s00261-007-9211-7.

43. Bamba Y, Itabashi M, and Kameoka S. Clinical use of PET/CT in peritoneal carcinomatosis from colorectal cancer. Hepato- Gastroenterology. 2012; 59(117):1408–1411. doi: 10.5754/hge11640

44. Choi EK, Yoo IR, Park HL, et al. Value of surveillance 18F-FDG PET/CT in colorectal cancer: comparison with conventional imaging studies. Nuclear Medicine and Molecular Imaging. 2012; 46(3):189–195. doi: 10.1007/s13139-012-0145-9.

45. Brendle C, Schwenzer NF, Rempp H, et al. Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. European Journal of Nuclear Medicine and Molecular Imaging. 2016; 43(1): 123–132. doi: 10.1007/s00259-015-3137-z

46. Satoh Y, Ichikawa T, Motosugi U, et al. Diagnosis of peritoneal dissemination: comparison of 18F-FDG PET/CT, diffusion-weighted MRI, and contrast-enhanced MDCT. American Journal of Roentgenology. 2011; 196(2): 447– 453. doi: 10.2214/AJR.10.4687

47. Dohan A, Hoeffel C, Soyer P, et al. Evaluation of the peritoneal carcinomatosis index with CT and MRI,” The British Journal of Surgery. 2017; 104(9): 1244–1249. doi: 10.1002/bjs.10527

48. Huang CJ, Jiang JK, Chang SC, et al. Yang. Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women. Medicine (Baltimore). 2016; 95(47): e5177. doi: 10.1097/MD.0000000000005177

49. Thomassen I, van Gestel YRBM, Aalbers AGJ, et al. Peritoneal carcinomatosis is less frequently diagnosed during laparoscopic surgery compared to open surgery in patients with colorectal cancer. European Journal of Surgical Oncology. 2014; 40(5): 511–514. doi: 10.1016/j.ejso.2014.01.013

50. Najah H, Lo Dico R, Dohan A, et al. A feasibility study of the use of computed virtual chromoendoscopy for laparoscopic evaluation of peritoneal metastases. Surgical Endoscopy. 2017; 31(2): 743–751. doi: 10.1007/s00464-016-5028-1.

51. Barabino G, Klein JP, Porcheron J, et al. Intraoperative near-infrared fluorescence imaging using indocyanine green in colorectal carcinomatosis surgery: proof of concept. European Journal of Surgical Oncology. 2016; 42(12): 1931–1937. doi: 10.1016/j.ejso.2016.06.389

52. Lieto E, Auricchio A, Cardella F, et al. Fluorescence-guided surgery in the combined treatment of peritoneal carcinomatosis from colorectal cancer: preliminary results and considerations. World Journal of Surgery. 2018; 42(4): 1154–1160. doi: 10.1007/s00268-017-4237-7.

53. Liberale G, Vankerckhove S, Caldon MG, et al. Fluorescence imaging after indocyanine green injection for detection of peritoneal metastases in patients undergoing cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer: a pilot study. Annals of Surgery. 2016; 264(6): 1110–1115. doi: 10.1097/SLA.0000000000001618.

54. Harlaar NJ, Koller M, de Jongh SJ, et al. Molecular fluorescence-guided surgery of peritoneal carcinomatosis of colorectal origin: a single-centre feasibility study. The Lancet Gastroenterology & Hepatology. 2016; 1(4): 283–290. doi: 10.1016/S2468-1253(16)30082-6.

55. Taylor F, Mangat N, Swift IR, and Brown G. Proforma based reporting in rectal cancer. Cancerimaging. 2010; 10(1A): S142–S150. doi: 10.1102/1470-7330.2010.9092

56. Chandramohan A, Thrower A, Smith SA, et al. ‘PAUSE’: a method for communicating radiological extent of peritoneal malignancy. Clinical Radiology. 2017; 72(11): 972–980. doi: 10.1016/j.crad.2017.07.005.

57. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classifycation. Jpn J Surg. 1981;11(2):127–39. doi: 10.1007/BF02468883.

58. Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41(2):124–9.

59. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374. doi: 10.1007/978-1-4613-1247-5_23.

60. Witkamp AJ, de Bree E, Kaag MM, et al. Extensive cytoreductive surgery followed by intraoperative hyperthemic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer. 2013;37(8):979–84. :https://doi.org/10.1016/S0959-8049(01)00058-2.

61. Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012; 30: 263-267. doi: 10.1200/JCO.2011.37.1039.

62. Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014 Aug;21(8):2608-14. doi: 10.1245/s10434-014-3647-0.

63. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26(33):5344-51. doi: 10.1200/JCO.2008.17.5299.

64. Kohne CH, Cunningham D, Di Costanzo F, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol. 2002;13(2):308-17. doi: 10.1093/annonc/mdf034.

65. Chua TC, Morris DL, Saxena A, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol. 2011;18(6):1560-7. doi: 10.1245/s10434-010-1522-1.

66. Go PH, Klaassen Z, Meadows MC, Chamberlain RS. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer. 2011; 117: 3630-3640. doi: 10.1002/cncr.25940.

67. Lemmens VE, Klaver YL, Verwaal VJ, et al. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011; 128: 2717-2725. doi: 10.1002/ijc.25596.

68. Marques RP, Duarte GS, Sterrantino C, et al. Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2017 Oct;118:54-62. doi: 10.1016/j.critrevonc.2017.08.006.

69. Cremolini C, Antoniotti C, Lonardi S, et al. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. Ann Oncol. 2018 Jul;29(7):1528-1534. doi: 10.1093/annonc/mdy140.

70. Hurwitz HI, Tan BR, Reeves JA, et al. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM). Oncologist. 2019 Jul;24(7):921-932. doi: 10.1634/theoncologist.2018-0344.

71. Schmoll H-J, Meinert FM, Cygon F, et al: “CHARTA”: FOLFOX/bevacizumab vs FOLFOXIRI/bevacizumab in advanced colorectal cancer - Final results, prognostic and potentially predictive factors from the randomized phase II trial of the AIO. Journal of Clinical Oncology. 2017 suppl (May 20,) 35(15): 3533-3533. DOI: 10.1200/JCO.2017.35.15_suppl.3533.

72. SastreJ, VieitezJM, Gomez-EspañaMA, et al. Randomized phase III study comparing FOLFOX + bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs). Journal of Clinical Oncology. 2019;37(15) suppl:3507-3507. DOI: 10.1200/JCO.2019.37.15_suppl.3507.

73. Birnleitner H, Sachet M, Bachleitner-Hofmann T, Oehler R. Immunogenic effects of FOLFOXIRI plus Bevacizumab therapy in colorectal peritoneal carcinomatosis. The 6th Leading International Cancer Immunotherapy Conference in Europe. European Journal of Cancer. 2019;110:S1eS34. doi.org/10.1016/j.ejca.2019.01.039.

74. Федянин М.Ю., Гладков О.А., Гордеев С.С., Рыков И.В., Трякин А.А. и соавт. Практические рекомендации по лекарственному лечению рака ободочной кишки и ректосигмоидного соединения. Злокачественные опухоли: Практические рекомендации RUSSCO. #3s2, 2019 (т. 9), c.324–364. DOI: 10.18027 / 2224-5057-2019-9-3s2-324-364.

75. Modest DP, Martens UM, Riera-Knorrenschild J, et al. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109). J Clin Oncol. 2019 Dec 10;37(35):3401-3411. doi: 10.1200/JCO.19.01340.

76. Huabin Hu, Kun Wang, Wei Wang, et al. FOLFOXIRI with or without cetuximab as conversion therapy in patients with RAS/BRAF wild-type unresectable liver metastases colorectal cancer: The FOCULM study. Journal of Clinical Oncology. 2020 38(4):suppl:99-99. DOI: 10.1200/JCO.2020.38.4_suppl.99.

77. Lopez-CrapezE, AdenisA, ThezenasS, et al. FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial. Journal of Clinical Oncology. 2018;36(15):suppl:3548-354. DOI: 10.1200/JCO.2018.36.15_suppl.354.

78. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25:3456–3461.

79. Ychou M, Raoul JL, Douillard JY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol. 2009;20:674–680. doi: 10.1200/JCO.2007.11.2144.

80. van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer PETACC-3. J Clin Oncol. 2009;27:3117–3125. doi: 10.1200/JCO.2008.21.6663.

81. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol. 2009;20:1964–1970. doi: 10.1093/annonc/mdp236.

82. Bridgewater JA, Pugh SA, Maishman T, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020 Mar;21(3):398-411. doi: 10.1016/S1470-2045(19)30798-3.

83. Alberts SR, Sargent DJ, Smyrk TC, et al. Adjuvant mFOLFOX6 with or without Cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage II colon cancer (CC): result from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol. 2010;28(18):959s.

84. Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11–16. doi: 10.1200/JCO.2010.30.0855.

85. de Gramont A, van Cutsem E, Schmoll HJ, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225–1233. doi: 10.1016/S1470-2045(12)70509-0.

86. Lumachi F, Chiara GB, Tozzoli R, et al. Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis. Anticancer Res. 2016 Jan;36(1):13-9.

87. Kanas GP, Taylor A, Primrose JN, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol. 2012;4:283-301. doi: 10.2147/CLEP.S34285.

88. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29-42. doi: 10.1097/00000658-199501000-00004.

89. Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228-231. doi: 10.1002/jso.21068.

90. Dromain C, Caramella C, Dartigues P, et al. Liver, lung and peritoneal metastases in colorectal cancers: is the patient still curable? What should the radiologist know. Diagn Interv Imaging. 2014 May;95(5):513-23. doi: 10.1016/j.diii.2014.03.011.

91. Wademan M, Ha J, Singh H, et al. Current indications, techniques and results of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for intra-abdominal malignancies. SurgeryCurr Res. 2012, 2:4. DOI: 10.4172/2161-1076.1000125.

92. Sugarbaker PH. Prevention and Treatment of Peritoneal Metastases: a Comprehensive Review. Indian J Surg Oncol. 2019 Mar;10(1):3-23. doi: 10.1007/s13193-018-0856-1.

93. Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol. 2010; 7: 108-115. DOI:10.1038/nrclinonc.2009.217.

94. Karnofsky DA, AbelmannWH, Craver LF et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer. 1948;40:634–656.

95. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc. 1955;159:1704-1707. doi: 10.1001/jama.1955.02960350004002.

96. Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, et al. Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer. 1967;20:1351-1381. doi: 10.1002/1097-0142(196709)20:9<1351::aid-cncr2820200902>3.0.co;2-#.

97. Sticca RP, Dach BW. Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agents. Surg Oncol Clin N Am. 2003;12:689-701. doi: 10.1016/s1055-3207(03)00029-2.

98. Jones RB, Myers CE, Guarino AM et al. High volume intraperitoneal chemotherapy (“belly bath”) for ovarian cancer. Cancer Chemother Pharmacol. 1978;1:161–166. doi: 10.1007/BF00253116.

99. Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy (EPIC). Br J Surg. 1989;76:1082–1090. doi: 10.1002/bjs.1800761030.

100. SoJBY, JiJ, HanSU, et al. Extensive peritoneal lavage after curative gastrectomy for gastric cancer study (EXPEL): An international multicenter randomized controlled trial. Journal of Clinical Oncology. 2020;38(4):suppl:279-279. DOI: 10.1200/JCO.2020.38.4_suppl.279.

101. Emoto S, Sunami E, Yamaguchi H, et al. Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. SurgToday. 2014;44: 2209-2220. doi: 10.1007/s00595-014-0848-x.

102. Aoyagi T, Terracina KP, Raza A, Takabe K. Current treatment options for colon cancer peritoneal carcinomatosis. World J Gastroenterol. 2014 September 21; 20(35):12493-12500. . doi: 10.3748/wjg.v20.i35.12493.

103. Halkia E, Tsochrinis A, Vassiliadou DT, et al. Peritoneal carcinomatosis: intraoperative parameters in open (coliseum) versus closed abdomen Hipec. International Journal of Surgical Oncology. 2015, Article ID 610597, 6 pages. https://doi.org/10.1155/2015/610597.

104. Silva CR, F. Ruiz JM, and Estévez IB. Are there intra-operative hemodynamic differences between the Coliseum and closed HIPEC techniques in the treatment of peritoneal metastasis? A retrospective cohort study. World Journal of Surgical Oncology. 2017; 15(1): 51. doi: 10.1186/s12957-017-1119-2.

105. Spiliotis, A. Rogdakis, A. Vaxevanidou, A. Datsis, et al. Morbidity and mortality of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal carcinomatosis. Journal of B.U.ON. 2009; 14(2): 259–264.

106. Gupta N, Asif S, Gandhi J, et al. Role of CRS and HIPEC in appendiceal and colorectal malignancies: Indian experience. Indian Journal of Gastroenterology. 2017; 36(2): 126–130. doi: 10.1007/s12664-017-0747-3.

107. Facy O, Combier C, Poussier M, et al. High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery. 2015; 157(1): 72–78. doi: 10.1016/j.surg.2014.06.006.

108. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010; 28:63-68. doi: 10.1200/JCO.2009.23.9285.

109. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multiinstitutional study. J Clin Oncol. 2004; 22: 3284-3292. doi: 10.1200/JCO.2004.10.012.

110. Verwaal VJ, Bruin S, Boot H, et al.8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008; 15:2426-2432. doi: 10.1245/s10434-008-9966-2.

111. Wu W, Yan S, Liao H, et al. Curative versus palliative treatments for colorectal cancer with peritoneal carcinomatosis: a systemic review and meta-analysis. Oncotarget. 2017;8(68):113202-113212. doi: 10.18632/oncotarget.21912.

112. Kanemitsu Y, Shitara K, Mizusawa J, et al. A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: JCOG1007 study (iPACS). J Clin Oncol. 2020;38 (suppl 4; abstr 7). doi: 10.1093/jjco/hyz173.

113. Vaillant JC, Nordlinger B, Deuffic S, et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial. Ann Surg. 2000; 231: 449-456. doi: 10.1097/00000658-200004000-00001.

114. Nordlinger B, Rougier P, Arnaud JP, et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentrerandomised controlled phase III trial. Lancet Oncol. 2005; 6: 459-468. doi: 10.1016/S1470-2045(05)70222-9.

115. Quenet F, Goere D, Mehta SS, et al Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254: 294-301. doi: 10.1097/SLA.0b013e3182263933.

116. Prada-Villaverde A, Esquivel J, Lowy AM, et al. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with mitomycin C versusoxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110:779–785. doi: 10.1002/jso.23728.

117. Song N, Pogue-Geile KL, Gavin PG, et al. Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes: Secondary Analysis of NSABP C-07/NRG Oncology Randomized Clinical Trial. JAMA Oncol. 2016 Sep 1;2(9):1162-9. doi: 10.1001/jamaoncol.2016.2314.

118. Leung V, Huo YR, Liauw W, Morris DL. Oxaliplatin versus mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis. Eur J Surg Oncol. 2017;43:144–149. doi: 10.1016/j.ejso.2016.09.015.

119. Wisselink DD, Braakhuis LLF, Gallo G, et al. Systemic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal; chemotherapy in patients with peritoneal metastases from colorectal cancer. Critical reviews in oncology/hematology. 2019 Oct;142:119-129. doi: 10.1016/j.critrevonc.2019.06.014.

120. Sipok A, Sardi A, Nieroda C, et al. Comparison of survival in patients with isolated pperitonealcanceromatosis from colorectal cancer treated with cytoreduction and Melphalan or Mitomycin-C as hiperthermic intraperitoneal chemotherapy agent. Int J of Surg Oncol. 2018 articleID 1920276. doi: 10.1155/2018/1920276.

121. Ihemelandu C, Sugarbaker PH. Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades. Ann Surg Oncol. 2017 Apr;24(4):898-905. doi: 10.1245/s10434-016-5698-x.

122. Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. Journal of Clinical Oncology. 2018;36, no. 18_suppl. DOI: 10.1200/JCO.2018.36.18_suppl.LBA3503.

123. Klaver CEL, Wisselink DD, Punt CJA, et al. Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: Primary outcome of the COLOPEC multicenter randomized trial. J Clin Oncol. 2019:37 (suppl 4; abstr 482). DOI: 10.1200/JCO.2019.37.4_suppl.482

124. Goere D, GlehenO, QuenetF, et al. Results of a randomized phase 3 study evaluating the potential benefit of a second-look surgery plus HIPEC in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP- NTC01226394). Journal of Clinical Oncology. 2018;36, no. 15_suppl:3531-3531. DOI: 10.1200/JCO.2018.36.15_suppl.3531.

125. Elias D, Delperro JR, Sideris L, et al. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol. 2004; 11: 518-521. doi: 10.1245/ASO.2004.09.008.

126. Mahteme H, Hansson J, Berglund A, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer. 2004; 90: 403-407. doi: 10.1038/sj.bjc.6601586.

127. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006; 24: 4011-4019. DOI: 10.1200/JCO.2006.07.1142.

128. McConnell YJ, Mack LA, Francis WP, et al. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol. 2013;107:591–596. doi: 10.1002/jso.23276.

129. Khosrawipour V, Khosrawipour T, Kern AJP, et al. Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. Journal of Cancer Research and Clinical Oncology. 2016;142(11): 2275–2280. doi: 10.1007/s00432-016-2234-0.

130. Robella M, Vaira M, and De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an Gastroenterology Research and Practice innovative approach to treat peritoneal carcinomatosis. World Journal of Surgical Oncology. 2016; 14:p.128. doi: 10.1186/s12957-016-0892-7.

131. Tempfer CB, Solass W, Buerkle B, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in a woman with pseudomyxoma peritonei: A case report. Gynecol Oncol Rep. 2014;10:32–5. doi: 10.1016/j.gore.2014.10.001.

132. Alyami M, Gagniere J, Sgarbura O, et al. Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. European Journal of Surgical Oncology. 2017; vol. 43, no. 11, pp. 2178–2183. doi: 10.1016/j.ejso.2017.09.010.

133. Demtröder C, Solass W, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Colorectal Disease. 2016; 18(4): 364–371. doi: 10.1111/codi.13130.

134. Kakchekeeva T, Demtroder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an adjunct to Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC). Ann Surg Oncol. 2016;23:S592–8. doi: 10.1245/s10434-016-5108-4.

135. Sugarbaker PH. Normothermic intraperitoneal chemotherapy long term (NIPEC-LT) in the management of peritoneal surface malignancy, an overview. Pleura and Peritoneum. 2017;2:85–93. doi: 10.1515/pp-2017-0012.

136. Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. J Clin Oncol. 2018 Jul 1;36(19):1922-1929. doi: 10.1200/JCO.2018.77.8613.

137. Armstrong DK, Walker JL. Role of Intraperitoneal therapy in the initial management of ovarian cancer. J Clin Oncol. 2019 Sep 20;37(27):2416-2419. DOI: 10.1200/JCO.19.00671.

138. Braam HJ, Boerma D, Wiezer MJ, Ramshorst V. Hyperthermic intraperitoneal chemotherapy during primary tumour resection limits extent of bowel resection compared to two-stage treatment. Eur J Surg Oncol. 2013;39:988–993. doi: 10.1016/j.ejso.2013.06.002.

139. Froysnes I, Larsen S, Spasojevic M, et al. Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: prognostic factors and oncologic outcome in a national patient cohort. J Surg Oncol. 2016 Aug;114(2):222-7. doi: 10.1002/jso.24290.

140. Faron M, Macovei R, Goere D, et al. Linear relationship of peritoneal cancer index and survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23:114–9. doi: 10.1245/s10434-015-4627-8.

141. Paul BK, Ihemelandu C, Sugarbaker PH. Prior surgical score: an analysis of the prognostic significance of an initial nondefinitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy. Dis Colon Rectum. 2018 Mar;61(3):347-354. doi: 10.1097/DCR.0000000000001003.

142. Bachet JB, Moreno-Lopez N, Vigano L, et al. BRAF mutation is not associated with an increased risk of recurrence in patients undergoing resection of colorectal liver metastases. Br J Surg. 2019 Aug;106(9):1237-1247. doi: 10.1002/bjs.11180.

143. Alzahrani NA, Valle SJ, Fisher OM, et al. Iterative cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: A multi‐institutional experience. J Surg Oncol. 2018;1-11. doi: 10.1002/jso.25277.

144. Braam HJ, van Oudheusden TR, de Hingh IHJT, et al. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. J Surg Oncol. 2014; 109:841‐847. doi: 10.1002/jso.23597.

145. Piso P, Stierstorfer K, Gerken M, Klinkhammer‐Schalke M. Benefit of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with isolated peritoneal metastases from colorectal cancer. Int J Colorectal Dis. 2018;33 (11):1559‐1567. doi: 10.1007/s00384-018-3146-z.

146. van Eden WJ, Elekonawo FMK, Starremans BJ, et al. Treatment of isolated peritoneal recurrences in patients with colorectal peritoneal metastases previously treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2018;25:1992‐2001. doi: 10.1245/s10434-018-6423-8.

147. Sugarbaker PH. Pharmacology of chemotherapy treatments for peritoneal metastases: optimizing and augmenting HIPEC. Pleura Peritoneum. 2017 Jun 1; 2(2): 43–45. doi: 10.1515/pp-2017-0011.

148. Тер-Ованесов М.Д., Буйденок Ю.В., Полоцкий Б.Е. и соавт. Гипертермическая интраперитонеальная химиоперфузия (ГИИХ - HIPEC) в комбинированном лечении местнораспространенного и интраперитонеально диссеминированного рака желудка и других форм опухолей. Российская Онкологическая Конференция, Ноябрь, 2007г.


Для цитирования:


Федянин М.Ю., Трякин А.А., Тер-Ованесов М.Д., Тюляндин С.А. ДИАГНОСТИКА, ЛЕЧЕНИЕ И ПРОГНОЗ У ПАЦИЕНТОВ С КАНЦЕРОМАТОЗОМ БРЮШИНЫ ПРИ КОЛОРЕКТАЛЬНОМ РАКЕ (обзор литературы). Колопроктология. 2020;19(4):131-149. https://doi.org/10.33878/2073-7556-2020-19-4-131-149

For citation:


Fedyanin M.Yu., Tryakin A.A., Ter-Ovanesov M.D., Tyulyandin S.A. DIAGNOSTICS, TREATMENT AND PROGNOSIS IN PATIENTS WITH COLORECTAL CANCER AND PERITONEAL CARCINOMATOSIS (review). Koloproktologia. 2020;19(4):131-149. (In Russ.) https://doi.org/10.33878/2073-7556-2020-19-4-131-149

Просмотров: 149


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2073-7556 (Print)
ISSN 2686-7303 (Online)